MOSCOW--(Marketwired - Jun 24, 2013) - Cromos Pharma, a full service regional contract research organization (CRO), announced today that it has begun operations in the Republic of Belarus. These operations are being conducted through Cromos Pharma's office in the city of Smolensk, Russia.
"When it comes to clinical research, Belarus has many attractive attributes," noted Dr. Vladimir Bogin, Chief Executive Officer of Cromos Pharma. "Belarus has a developed healthcare system, well-trained medical professionals with good knowledge of ICH/GCP and standards of care that are comparable to European medical practice," continued Dr. Bogin.
"Recent legislative concessions allow for a significant increase in the reimbursement of study teams. This signifies a substantial shift in state policy towards clinical research and has sparked a renewed interest in clinical trials by both medical centers and investigators," said Cromos Pharma's Managing Director, Andrey Tarakanov, MD. "The staff of our Smolensk office has considerable experience in all stages of clinical trial conduct in Belarus, and Cromos Pharma has a strong working relationship with local medical centers and investigators," he continued.
"Recent addition of Georgia and now of Belarus to its geographic footprint will allow Cromos Pharma to compete for even larger multi-center, international clinical trials," concluded Dr. Bogin.
Cromos Pharma has recently published a white paper which provides comprehensive updates on the Belarusian regulatory changes along with a brief overview of its healthcare system.
About Cromos Pharma, LLC
Cromos Pharma, LLC is a contract research organization (CRO) with operations in Russia, Ukraine and Eastern Europe and a business development office in the United States. The company provides a full spectrum of trial-related services which include regulatory approvals, medical writing, feasibility assessments, monitoring, project management and warehousing. Cromos Pharma, LLC is a privately owned company.